Dr. Muhammad Wahajuddin

Biography

Dr Wahajuddin joined the Institute of Cancer Therapeutics from India after serving as Principal Scientist at the Pharmaceutics & Pharmacokinetics Division, CSIR- Central Drug Research Institute Lucknow. As well as being a registered pharmacist in India, he is a registered patent agent with the Indian patent office, New Delhi. He had previously worked (2013-14) as a visiting scientist at UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA and as Humboldt Research Fellow at University of Cologne Hospital's Centre for Pharmacology, Cologne, Germany (2018-19). Dr Wahajuddin has published more than 150 research papers in highly reputed peer reviewed international journals, nine book chapters and edited two books. He has also won many awards and accolades like the Young Scientist Award 2013-14 from the State Government of Uttar Pradesh India, the Shakuntala Amir Chand Prize 2019 for Young Scientist by the Indian Council of Medical Research (ICMR) Govt. of India, Young Pharmaceutical Analyst Award 2012 from the Indian Drug Manufacturer’s Association, DBT- Cutting-edge Research Enhancement & Scientific Training (DBT-CREST) Award 2011-12 from the Dept. of Biotech. Govt. of India, Junior Investigator Award 2017 from Safety Pharmacological Society USA and ISMAS Young Mass Spectroscopist Award 2013 from the Indian Society for Mass Spectrometry etc. He has been elected a member of the Global Young Academy under the aegis of German National Academy of Sciences, Leopoldina Halle, Germany, Indian National Young Academy of Sciences, National Academy of Sciences (India), National Academy of Medical Sciences (India) and was admitted as Fellow of Royal Society of Biology (UK), Royal Society of Chemistry (UK) and Higher Education Academy (UK). He is one of the co-leads of Science Diplomacy in South Asia, a working group of the Global Young Academy (2020-2021). He is editor/editorial board member of many reputed high-impact scientific journals like Current Pharmaceutical Design, Current Drug Delivery (Section Editor: Novel pharmaceutical strategies from nanotechniques for effective drug delivery), Recent Patents on Anti-Cancer Drug Discovery (Section Editor: Anti-infective Formulation), Frontiers in Nanotechnology (Review Editor for Biomedical Nanotechnology) and Pharmacognosy Magazine.

Research

Drug Discovery, Development, Delivery and Therapy.

Dr. Wahajuddin’s research is driven by a translational vision to bridge fundamental pharmacokinetic science with innovative therapeutic strategies, particularly in the domains of Drug Metabolism and Pharmacokinetics (DMPK), nanotechnology-enabled drug delivery, and oncology. His work integrates bioanalysis, formulation science, biopharmaceutics, and pharmacometrics to optimize drug efficacy and safety.

Key thematic areas include:

• Pharmacokinetics & DMPK: Comprehensive in vivo and in vitro characterization of drug absorption, distribution, metabolism, and excretion (ADME), with a focus on species scaling, transporter interactions, and metabolic profiling to inform human pharmacokinetics and precision dosing strategies.
• Nanotechnology in Drug Delivery: Development of smart nanocarriers for targeted and sustained delivery of chemotherapeutics and phytopharmaceuticals, aiming to overcome multidrug resistance and enhance therapeutic index.
• Cancer Therapeutics: Experimental therapeutic evaluation of novel anticancer modalities.
• Pharmacometrics & Systems Pharmacology: Application of PBPK/PBBM/PKPD modeling and simulation to support rational drug design, dose optimization, and model-informed precision medicine.
• Herb-Drug Interactions & Natural Product Pharmacology: Investigating the pharmacokinetic and pharmacodynamic interactions of phytochemicals with conventional drugs, particularly in the context of infectious diseases, metabolic disorders and cancer.

These research themes are underpinned by a strong track record of over 140 peer-reviewed publications, 8 patents, multiple technology transfers, and international collaborations, reflecting a commitment to impactful, interdisciplinary, and globally relevant pharmaceutical research.

At the University of Bradford Institute of Cancer Therapeutics, Dr Wahajuddin is studying pharmacokinetics and biopharmaceutics of potential onco-therapies (in addition to marketed drugs/metabolites/natural products) and deciphering the molecular mechanism(s) of ADME/disposition thereof.

Teaching

Pharmacology, Pharmaceutics, Pharmaceutical Analysis, Pharmacokinetics, Drug Metabolism, Biopharmaceutics, Drug Discovery & Development.